US7217549B2ExpiredUtilityA1

β 1,3-galactosyltransferases from C. jejuni

91
Assignee: CA NAT RESEARCH COUNCILPriority: Feb 1, 1999Filed: May 21, 2004Granted: May 15, 2007
Est. expiryFeb 1, 2019(expired)· nominal 20-yr term from priority
C12N 9/1051C12P 19/18C12N 9/1029C12N 9/1048C12N 9/1241C12N 9/1081
91
PatentIndex Score
11
Cited by
30
References
6
Claims

Abstract

This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an α2,3- and an α2,8-activity. A β1,4-GalNAc transferase and a β1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni . In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

Claims

exact text as granted — not AI-modified
1. An isolated or recombinantly produced protein comprising a β1,3-galactosyltransferase polypeptide, wherein the β1,3-galactosyltransferase polypeptide has an amino acid sequence that is at least about 95% identical to SEQ ID NO:31. 
     
     
       2. The isolated or recombinantly produced protein of  claim 1 , wherein the β1,3-galactosyltransferase polypeptide is SEQ ID NO: 31. 
     
     
       3. The isolated or recombinantly produced protein of  claim 1 , further comprising a tag for purification. 
     
     
       4. The isolated or recombinantly produced protein of  claim 1 , wherein the protein is recombinantly produced and at least partially purified. 
     
     
       5. The isolated or recombinantly produced protein of  claim 1 , wherein the protein is expressed by a heterologous host cell. 
     
     
       6. The isolated or recombinantly produced protein of  claim 5 , wherein the host cell is  E. coli.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.